Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Somatostatin Receptor Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT04104529
What this trial is testing

Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

Who this might be right for
Thyroid CancerProstate CancerNeuroendocrine Tumors+2 more
Institut du Cancer de Montpellier - Val d'Aurelle 350
Not applicableStudy completedNCT05844332
What this trial is testing

LUTATHERA Injection General Use Result Survey

Who this might be right for
Somatostatin Receptor-positive Neuroendocrine Tumor
Novartis Pharmaceuticals 347
Post-approval studies (Phase 4)Ended earlyNCT00944372
What this trial is testing

Study to Evaluate the Effect of Age (Geriatric) and Kidney Function on the Safety, Efficacy and Pharmacokinetics of OctreoScan in Patients Who Have New or Recurrent Tumors

Who this might be right for
Solid Tumors
Mallinckrodt 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT06590857
What this trial is testing

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Who this might be right for
Metastatic Breast CancerHER2-negative Breast CancerER+ Breast Cancer+7 more
RayzeBio, Inc. 16
Testing effectiveness (Phase 2)Study completedNCT01619865
What this trial is testing

Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorsNeuroblastoma+1 more
Sue O'Dorisio 223
Testing effectiveness (Phase 2)Looking for participantsNCT07129252
What this trial is testing

Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Who this might be right for
SST2-positive Neuroendocrine NeoplasmsNeuroendocrine TumorsNeuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc. 150
Testing effectiveness (Phase 2)Study completedNCT01869725
What this trial is testing

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Who this might be right for
Adult MedulloblastomaChildhood MedulloblastomaNeuroblastoma+2 more
Sue O'Dorisio 68
Testing effectiveness (Phase 2)Ended earlyNCT03145857
What this trial is testing

Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

Who this might be right for
Neuroendocrine Tumors
AHS Cancer Control Alberta 634
Not applicableApproved For MarketingNCT02705313
What this trial is testing

EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx

Who this might be right for
Neuroendocrine Tumors
Advanced Accelerator Applications
Large-scale testing (Phase 3)Study completedNCT01578239
What this trial is testing

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Who this might be right for
Carcinoid Tumor of the Small BowelNeuroendocrine Tumour
Advanced Accelerator Applications 231
Testing effectiveness (Phase 2)Looking for participantsNCT05636618
What this trial is testing

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Who this might be right for
Neuroendocrine Tumors UnresectableNeuroendocrine Tumor MetastaticGastroenteropancreatic Neuroendocrine Tumor+4 more
Perspective Therapeutics 300
Early research (Phase 1)UnknownNCT02845570
What this trial is testing

Evaluation of Somatostatin Receptor Imaging Using PET/MRI as a Novel Approach to Detecting Pathology in Pulmonary TB

Who this might be right for
Tuberculosis
National University Hospital, Singapore 8
Testing effectiveness (Phase 2)Ended earlyNCT02592707
What this trial is testing

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Who this might be right for
Neuroendocrine Tumors
Ipsen 40
Large-scale testing (Phase 3)Looking for participantsNCT05918302
What this trial is testing

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Who this might be right for
Neuroendocrine TumorsLung Neuroendocrine NeoplasmThymus Neoplasms
Grupo Espanol de Tumores Neuroendocrinos 170
Early research (Phase 1)Study completedNCT04375267
What this trial is testing

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

Who this might be right for
Clinical Trial, Phase INeuroendocrine TumorsThymoma+1 more
Vastra Gotaland Region 18
Large-scale testing (Phase 3)Looking for participantsNCT05884255
What this trial is testing

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Who this might be right for
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd. 220
Not applicableStudy completedNCT04946305
What this trial is testing

A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea

Who this might be right for
Somatostatin Receptor-positive GEP-NET
Novartis Pharmaceuticals 89
Testing effectiveness (Phase 2)Study completedNCT02162446
What this trial is testing

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 12
Not applicableActive Not RecruitingNCT02743741
What this trial is testing

Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
University Health Network, Toronto 195
Testing effectiveness (Phase 2)UnknownNCT05894486
What this trial is testing

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Peking University 40
Next Page